International Assets Investment Management LLC Has $26,000 Stake in Anixa Biosciences, Inc. (NASDAQ:ANIX)

International Assets Investment Management LLC lowered its stake in Anixa Biosciences, Inc. (NASDAQ:ANIX) by 70.9% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 11,000 shares of the company’s stock after selling 26,800 shares during the period. International Assets Investment Management LLC’s holdings in Anixa Biosciences were worth $26,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently made changes to their positions in the stock. Concorde Asset Management LLC bought a new position in shares of Anixa Biosciences in the 2nd quarter valued at approximately $31,000. Virtu Financial LLC acquired a new position in Anixa Biosciences during the third quarter valued at approximately $34,000. Westside Investment Management Inc. grew its holdings in Anixa Biosciences by 151.8% during the third quarter. Westside Investment Management Inc. now owns 35,000 shares of the company’s stock valued at $110,000 after purchasing an additional 21,100 shares during the last quarter. Finally, Tyler Stone Wealth Management raised its position in shares of Anixa Biosciences by 100.0% in the third quarter. Tyler Stone Wealth Management now owns 42,016 shares of the company’s stock valued at $132,000 after purchasing an additional 21,008 shares during the period. Institutional investors and hedge funds own 29.13% of the company’s stock.

Anixa Biosciences Price Performance

ANIX stock opened at $2.13 on Wednesday. The business has a fifty day moving average price of $2.89 and a 200 day moving average price of $3.03. Anixa Biosciences, Inc. has a fifty-two week low of $2.07 and a fifty-two week high of $5.13. The stock has a market capitalization of $68.54 million, a price-to-earnings ratio of -5.46 and a beta of 0.90.

Anixa Biosciences (NASDAQ:ANIX) last released its earnings results on Friday, January 10th. The company reported ($0.09) EPS for the quarter, beating the consensus estimate of ($0.11) by $0.02. On average, equities analysts expect that Anixa Biosciences, Inc. will post -0.42 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several research firms recently issued reports on ANIX. HC Wainwright reaffirmed a “buy” rating and set a $7.00 price objective on shares of Anixa Biosciences in a report on Tuesday, November 19th. D. Boral Capital restated a “buy” rating and set a $10.00 price target on shares of Anixa Biosciences in a report on Tuesday.

Anixa Biosciences Profile

Anixa Biosciences, Inc, a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell therapy, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer.